AI Article Synopsis
- - Synaptic damage, axonal neurodegeneration, and neuroinflammation are key features observed in Alzheimer's disease (AD), frontotemporal dementia (FTD), and Creutzfeldt-Jakob disease (CJD).
- - A study of 353 participants found significant differences in cerebrospinal fluid biomarkers between healthy controls and those with AD, FTD, and CJD, particularly noting that neurofilament light (NF-L) distinguished stages within the AD continuum.
- - The research highlights that biomarkers effectively differentiate between various neurodegenerative diseases and confirmed that NF-L and 14-3-3 proteins are as reliable as total tau in diagnosing neurodegeneration using the AT(N) system.
Article Abstract
Introduction: Synaptic damage, axonal neurodegeneration, and neuroinflammation are common features in Alzheimer's disease (AD), frontotemporal dementia (FTD), and Creutzfeldt-Jakob disease (CJD).
Methods: Unicentric cohort of 353 participants included healthy control (HC) subjects, AD continuum stages, genetic AD and FTD, and FTD and CJD. We measured cerebrospinal fluid neurofilament light (NF-L), neurogranin (Ng), 14-3-3, and YKL-40 proteins.
Results: Biomarkers showed differences in HC subjects versus AD, FTD, and CJD. Disease groups differed between them except AD versus FTD for YKL-40. Only NF-L differed between all stages within the AD continuum. AD and FTD symptomatic mutation carriers presented differences with respect to HC subjects. Applying the AT(N) system, 96% subjects were positive for neurodegeneration if 14-3-3 was used, 94% if NF-L was used, 62% if Ng was used, and 53% if YKL-40 was used.
Discussion: Biomarkers of synapse and neurodegeneration differentiate HC subjects from neurodegenerative dementias and between AD, FTD, and CJD. NF-L and 14-3-3 performed similar to total tau when AT(N) system was applied.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jalz.2019.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Better cardiovascular health is associated with slowed clinical progression in autosomal dominant frontotemporal lobar degeneration variant carriers.
Alzheimers Dement
October 2024
Department of Neurology, University of California, San Francisco, Memory and Aging Center, San Francisco, California, USA.
Article Synopsis
- - Cardiovascular health, evaluated through Life's Simple 7 (LS7), is linked to slower cognitive decline and better brain integrity in patients with autosomal dominant frontotemporal lobar degeneration (FTLD).
- - A study involving 247 FTLD genetic variant carriers and 189 non-carrier controls found that those with better cardiovascular health had slower memory and language declines, as well as less accumulation of frontal white matter hyperintensities (WMHs).
- - Maintaining good cardiovascular health could be a key modifiable strategy to improve cognitive outcomes and brain health in individuals at risk for genetic forms of dementia.
Article Synopsis
- The study investigates the effect of a specific genetic modifier on gray matter volume and cognitive function in patients with Frontotemporal Lobar Degeneration (FTLD), including both mutation carriers and sporadic cases.
- Participants were recruited from the ALLFTD study and were genotyped for the rs1990622 SNP to assess the relationship between this genetic variant and cognitive outcomes across different genetic groups.
- Findings indicate that the minor allele of rs1990622 is associated with increased gray matter volume and better cognitive scores in mutation carriers, especially affecting the thalamus, suggesting it may play a role in modifying the risk and impact of FTLD.
Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration.
JAMA Netw Open
April 2024
Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Article Synopsis
- Frontotemporal lobar degeneration (FTLD) is a rare condition characterized by behavioral and motor symptoms, making traditional neuropsychological assessments less effective for early detection; smartphone-based cognitive tests may provide a solution for remote evaluations.
- A study conducted over four years involved 360 participants with varying stages of FTLD using smartphone apps to assess cognitive function, splitting them into discovery and validation groups, with a majority being asymptomatic or at preclinical stages.
- Results indicate the smartphone-based tests showed moderate to excellent reliability in measuring cognitive function, suggesting they could serve as valid tools for remote assessments in FTLD patients.
Blood Neurofilament Light Chain in Different Types of Dementia.
Curr Alzheimer Res
August 2023
Department of Neurology, Tianjin Huanhu Hospital, 300222, Tianjin, China.
Aims: The study aimed to evaluate diagnostic values of circulating neurofilament light chain (NFL) levels in different types of dementia.
Background: Previous studies reported inconsistent change of blood NFL for different types of dementia, including Alzheimer's disease (AD), frontotemporal dementia (FTD), Parkinson's disease dementia (PDD) and Creutzfeldt-Jakob disease (CJD) and Lewy body dementia (LBD).
Objective: Meta-analysis was conducted to summarize the results of studies evaluating diagnostic values of circulating NFL levels in different types of dementia to enhance the strength of evidence.
Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research.
Alzheimers Dement (Amst)
May 2023
Department of Neurology, Memory and Aging Center, University of California, San Francisco Weill Institute for Neurosciences San Francisco California USA.
Introduction: Remote smartphone assessments of cognition, speech/language, and motor functioning in frontotemporal dementia (FTD) could enable decentralized clinical trials and improve access to research. We studied the feasibility and acceptability of remote smartphone data collection in FTD research using the ALLFTD Mobile App (ALLFTD-mApp).
Methods: A diagnostically mixed sample of 214 participants with FTD or from familial FTD kindreds (asymptomatic: CDR®+NACC-FTLD = 0 [ = 101]; prodromal: 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!